RxDoctor Payments Data

Jonathan Edwards, MD

Family Medicine · Athens, TXNPI 1720097298

Payments from drug & device makers

$1,024in general payments, 2019–2025

Across 51 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$150
  • AbbVie$107
  • Vanda Pharmaceuticals Inc.$87
  • Boehringer Ingelheim$72
  • Otsuka America Pharmaceutical, Inc.$64
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$59
  • plus $486 from 18 others

What the payments were for

  • Speaking & faculty fees$15015%
  • Food & beverage$87485%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,024 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$680,526
Medicare patients
1,105
Services billed
11,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide23$34,296
EliquisApixaban76$29,105
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,779
TrulicityDulaglutide21$15,473
OzempicSemaglutide15$15,454
LinzessLinaclotide27$15,059
JardianceEmpagliflozin46$13,693
MyrbetriqMirabegron31$11,973
XareltoRivaroxaban37$10,640
RybelsusSemaglutide11$9,964
JanuviaSitagliptin Phosphate21$7,589
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen173$6,797
Divalproex Sodium117$6,421
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,076
Pantoprazole Sodium223$5,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$45$25,41826 claims
Lilly USA, LLCTrulicity$13$15,47321 claims
AbbVieLinzess$107$15,05927 claims
Boehringer IngelheimJardiance$72$13,69346 claims
MerckJanuvia, Belsomra$13$12,54333 claims
Astellas Pharma US IncMyrbetriq$45$11,97331 claims
Johnson & JohnsonXarelto$14$10,64037 claims
Amneal Pharmaceuticals LLCRytary, Levothyroxine Sodium$33$9,486425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Athens

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →